Please login to the form below
Biogen
This page shows the latest Biogen news and features for those working in and with pharma, biotech and healthcare.
Biogen’s Vumerity recommended by CHMP in MS
A thumbs up for Vumerity in the EU could ease the way for Biogen’s follow-up to Tecfidera in multiple sclerosis. ... kinase inhibitor (BTKi) to treat MS, allowing Biogen to expand its MS pipeline portfolio.
Latest news
-
Embattled Biogen talks up Aduhelm
Biogen CEO admitted the company was experiencing “near-term challenges” after the controversial approval of Alzheimer’s drug, Aduhelm. ... After the Biogen leaders spoke about Aduhelm at the Morgan Stanley event the company’s shares were down by 7
-
Biogen and Eisai present new data for controversial Alzheimer's drug Aduhelm at AAIC
of our findings,” said Alfred Sandrock head of research and development at Biogen. ... This will include an ‘ongoing focus on interactions’ between Biogen and FDA staff during the review process.
-
Biogen and Ionis post ‘encouraging’ early results for Alzheimer’s disease candidate
Biogen and Ionis have revealed topline data from an early-stage study evaluating its investigational Alzheimer’s disease drug candidate BIIB080 (IONIS-MAPT Rx). ... In June, Biogen’s aducanumab was approved with the brand name Aduhelm for the
-
Roche engaged in talks with FDA for Alzheimer’s drug candidate
The recent US Food and Drug Administration (FDA) approval of Biogen’s Aduhelm for Alzheimer’s disease has renewed hopes for the anti-amyloid field, although the decision to approve the
-
FDA leaders offer perspective on accelerated approval of Biogen’s Aduhelm
Woodcock has asked for the process for review of Biogen’s biologics licence application (BLA) for Aduhelm to be investigated. ... This will include an ‘ongoing focus on interactions’ between Biogen and FDA staff during the review process.
Embattled Biogen talks up Aduhelm
Biogen and Eisai present new data for controversial Alzheimer's drug Aduhelm at AAIC
Roche engaged in talks with FDA for Alzheimer’s drug candidate
FDA leaders offer perspective on accelerated approval of Biogen’s Aduhelm
More from news
Approximately 154 fully matching, plus 322 partially matching documents found.
Latest Intelligence
-
After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream
Another example is Biogen’s $800m acquisition of Nightstar’s late-stage gene therapy assets for retinal disease – NSR-REP1 and NSR-RPGR.
-
Switzerland: a life sciences hub
The country is thus home to AbbVie, Allergan, Amgen, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Lundbeck, MSD (Merck Sharp &Dohme), Pfizer, Sanofi and Takeda among others.
-
Alzheimer’s: the search for a cure
The whiplash turnaround is the result of Biogen’s analysis of data from two phase 3 trials. ... Baird analyst Brian Skorney is among the people who have a dim view of Biogen’s prospects.
-
20 for 2020 – Five pharma leaders to watch in 2020
Analysts think the deal could catapult Galapagos into the top tier of biopharma companies, joining the likes of Regeneron, Biogen and Roche’s Genentech unit, providing its pipeline delivers as hoped
-
Great expectations: the urgent need for common purpose in Alzheimer’s disease
Biogen surprised the world last autumn by announcing a re-evaluation of its latest aducanumab trial and the company is now expected to apply for regulatory approval.
After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream
Switzerland: a life sciences hub
Alzheimer’s: the search for a cure
20 for 2020 – Five pharma leaders to watch in 2020
Great expectations: the urgent need for common purpose in Alzheimer’s disease
More from intelligence
Approximately 2 fully matching, plus 45 partially matching documents found.
Latest appointments
-
BMS appoints new commercial leader, Davies joins Eisai and more
operations. She joins Sobi from Biogen, where she served as vice president for global supply chain operations and strategic partnerships.
-
Biogen appoints executive VP, corporate development
Biogen has appointed Daniel Karp as its executive vice president, corporate development effective 11 June. ... He will also become a member of the executive committee and will report directly to chief executive officer Michel Vounatsos, who said: “We
-
Gamida Cell strengthens leadership team
Nee will lead market research, analytics, forecasting, commercial strategies and competitive intelligence at the company, activities he has practised during his time with Biogen, Amgen and Novartis.
-
Editas Medicine names James Mullen as chairman
Before joining Patheon, Mullen served as chief executive officer and president at Biogen and before this he held numerous roles at the biotech.
-
Acumen appoints new strategy director
Thomas Bols will focus on reinforcing Acumen’s healthcare practice
BMS appoints new commercial leader, Davies joins Eisai and more
Biogen appoints executive VP, corporate development
Gamida Cell strengthens leadership team
Editas Medicine names James Mullen as chairman
Acumen appoints new strategy director
More from appointments
Approximately 16 fully matching, plus 32 partially matching documents found.
Latest from PMHub
-
Mednet Group
Alzheimer’s Research UK. Alzheimer’s Society. Basic Needs. Biogen. Butterfly Scheme. Cardiomyopathy UK.
-
EPG Health
Strategic planning - to ensure ongoing engagement and success. Alexion, Almirall, Alnylam, AstraZeneca, Bial, Biogen, Bluebird Bio, Boehringer Ingelheim, BMS, CSL Behring, Ferring, Four Health, GSK, HRA Pharma, Janssen, Leo Pharma, Lilly,
-
Article: Market access in Brazil
In April 2019, Brazilian Health Minister Luiz Henrique Mandetta announced a pilot agreement for access to Biogen’s Spinal Muscular Atrophy (SMA) treatment Spinraza (nusinersen) through the Sistema Único de Saúde
-
IGNIFI
Allergan. Biogen. Boehringer Ingelheim. CO.DON. Danone Nutricia. Ferring Pharmaceuticals. Kyowa Kirin.
-
Wallace Health
Our expertise spans healthcare providers, pharmaceuticals and consumer health and we work for clients including HCA Hospitals, Alliance Medical, GSK and Biogen as well as high-performing start-ups such as
Mednet Group
EPG Health
IGNIFI
More from PMHub
Approximately 1 fully matching, plus 10 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- EU “still interested” in Valneva COVID vaccine despite UK snub
- US demand for COVID-19 antibody treatments rising fast
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- Havas Life Medicom and ARK lead at 2021 PM Society Digital Awards
- Healthcare Access and Payment Reform in the US
- Advancing Drug Discovery with Structured and Intelligent Data
- Fishawack Health appoints Elizabeth Landon in the newly created Chief People Officer role
- Gilead’s Veklury (remdesivir) cuts risk of severe COVID-19 by 87%
- Amgen’s Biosimilar Trends Report shows benefit of competition from biosimilars
- Cuttsy+Cuttsy awarded Gold accreditation by Investors in People
No results were found
PMHub
Madmicrobe Studios - Medical Animation
MadMicrobe is an award-winning team of certified medical illustrators creating animations that engage your audience with immersive experiences that bring...
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
